No significant strengths identified
| Dec 2023 | Dec 2024 | |
|---|---|---|
| Sales/Revenue | 5M | 7M |
| Revenue Growth % | - | 0.4% |
| Cost of Goods Sold | 1M | 1.29M |
| COGS % of Revenue | 0.2% | 0.18% |
| Gross Profit | 4M | 5.71M |
| Gross Margin % | 0.8% | 0.82% |
| Gross Profit Growth % | - | 0.43% |
| Operating Expenses | 41.85M | 75.73M |
| OpEx % of Revenue | 8.37% | 10.82% |
| Selling, General & Admin | 9.85M | 11.48M |
| SG&A % of Revenue | 1.97% | 1.64% |
| Research & Development | 32M | 64.24M |
| R&D % of Revenue | 6.4% | 9.18% |
| Other Operating Expenses | 0 | 0 |
| Operating Income | -37.85M | -70.01M |
| Operating Margin % | -7.57% | -10% |
| Operating Income Growth % | - | -0.85% |
| EBITDA | -36.85M | -68.73M |
| EBITDA Margin % | -7.37% | -9.82% |
| EBITDA Growth % | - | -0.87% |
| D&A (Non-Cash Add-back) | 1M | 1.29M |
| EBIT | -33.99M | -66.77M |
| Net Interest Income | 3.8M | 3.21M |
| Interest Income | 3.86M | 3.24M |
| Interest Expense | 58K | 34K |
| Other Income/Expense | 3.8M | 3.2M |
| Pretax Income | -34.05M | -66.81M |
| Pretax Margin % | -6.81% | -9.54% |
| Income Tax | 0 | 0 |
| Effective Tax Rate % | 1% | 1% |
| Net Income | -34.05M | -66.81M |
| Net Margin % | -6.81% | -9.54% |
| Net Income Growth % | - | -0.96% |
| Net Income (Continuing) | -34.05M | -66.81M |
| Discontinued Operations | 0 | 0 |
| Minority Interest | 0 | 0 |
| EPS (Diluted) | -1.13 | -2.27 |
| EPS Growth % | - | -1.01% |
| EPS (Basic) | -1.13 | -2.27 |
| Diluted Shares Outstanding | 30.08M | 30.08M |
| Basic Shares Outstanding | 30.08M | 30.08M |
| Dividend Payout Ratio | - | - |
| Dec 2023 | Dec 2024 | |
|---|---|---|
| Total Current Assets | 80.03M | 73.99M |
| Cash & Short-Term Investments | 79.08M | 72.04M |
| Cash Only | 29.02M | 16.25M |
| Short-Term Investments | 50.06M | 55.78M |
| Accounts Receivable | 0 | 0 |
| Days Sales Outstanding | - | - |
| Inventory | 0 | 0 |
| Days Inventory Outstanding | - | - |
| Other Current Assets | 948K | 1.95M |
| Total Non-Current Assets | 2.22M | 2.07M |
| Property, Plant & Equipment | 1.97M | 1.8M |
| Fixed Asset Turnover | 2.54x | 3.89x |
| Goodwill | 0 | 0 |
| Intangible Assets | 0 | 0 |
| Long-Term Investments | 208K | 208K |
| Other Non-Current Assets | 44K | 61K |
| Total Assets | 82.25M | 76.06M |
| Asset Turnover | 0.06x | 0.09x |
| Asset Growth % | - | -0.08% |
| Total Current Liabilities | 6.86M | 27.98M |
| Accounts Payable | 1.76M | 8.26M |
| Days Payables Outstanding | 641.67 | 2.34K |
| Short-Term Debt | 769K | 1.02M |
| Deferred Revenue (Current) | 0 | 1000K |
| Other Current Liabilities | 1.89M | 12.06M |
| Current Ratio | 11.67x | 2.64x |
| Quick Ratio | 11.67x | 2.64x |
| Cash Conversion Cycle | - | - |
| Total Non-Current Liabilities | 153.11M | 192.31M |
| Long-Term Debt | 149.37M | 191.78M |
| Capital Lease Obligations | 487K | 519K |
| Deferred Tax Liabilities | 0 | 0 |
| Other Non-Current Liabilities | 245K | 16K |
| Total Liabilities | 159.96M | 220.29M |
| Total Debt | 150.63M | 193.31M |
| Net Debt | 121.61M | 177.06M |
| Debt / Equity | - | - |
| Debt / EBITDA | - | - |
| Net Debt / EBITDA | - | - |
| Interest Coverage | -652.59x | -2059.21x |
| Total Equity | -77.71M | -144.24M |
| Equity Growth % | - | -0.86% |
| Book Value per Share | -2.58 | -4.80 |
| Total Shareholders' Equity | -77.71M | -144.24M |
| Common Stock | 1K | 1K |
| Retained Earnings | -83.91M | -152.22M |
| Treasury Stock | 0 | 0 |
| Accumulated OCI | 0 | 0 |
| Minority Interest | 0 | 0 |
| Dec 2023 | Dec 2024 | |
|---|---|---|
| Cash from Operations | -29.97M | -58.2M |
| Operating CF Margin % | -5.99% | -8.31% |
| Operating CF Growth % | - | -0.94% |
| Net Income | -34.05M | -66.81M |
| Depreciation & Amortization | 1M | 1.29M |
| Stock-Based Compensation | 0 | 0 |
| Deferred Taxes | 0 | 0 |
| Other Non-Cash Items | -261K | -98K |
| Working Capital Changes | 3.34M | 7.42M |
| Change in Receivables | 0 | 0 |
| Change in Inventory | 0 | 0 |
| Change in Payables | 125K | 6.51M |
| Cash from Investing | -48.43M | -3.99M |
| Capital Expenditures | -118K | -88K |
| CapEx % of Revenue | 0.02% | 0.01% |
| Acquisitions | - | - |
| Investments | - | - |
| Other Investing | 0 | 0 |
| Cash from Financing | 63.75M | 49.42M |
| Debt Issued (Net) | - | - |
| Equity Issued (Net) | - | - |
| Dividends Paid | 0 | 0 |
| Share Repurchases | - | - |
| Other Financing | -230K | -423K |
| Net Change in Cash | - | - |
| Free Cash Flow | -30.09M | -58.28M |
| FCF Margin % | -6.02% | -8.33% |
| FCF Growth % | - | -0.94% |
| FCF per Share | -1.00 | -1.94 |
| FCF Conversion (FCF/Net Income) | 0.88x | 0.87x |
| Interest Paid | 0 | 0 |
| Taxes Paid | 0 | 0 |
| Metric | 2023 | 2024 |
|---|---|---|
| Return on Invested Capital (ROIC) | - | -136.9% |
| Gross Margin | 80% | 81.61% |
| Net Margin | -681.06% | -954.4% |
| Interest Coverage | -652.59x | -2059.21x |
| FCF Conversion | 0.88x | 0.87x |
| Revenue Growth | - | 40% |
Evommune, Inc. (EVMN) reported $7.0M in revenue for fiscal year 2024. This represents a 40% increase from $5.0M in 2023.
Evommune, Inc. (EVMN) grew revenue by 40.0% over the past year. This is strong growth.
Evommune, Inc. (EVMN) reported a net loss of $66.8M for fiscal year 2024.
Evommune, Inc. (EVMN) had negative free cash flow of $58.3M in fiscal year 2024, likely due to heavy capital investments.